Skip to main content

Market Overview

UPDATE: MLV & Co. Initiates Coverage On Sorrento Therapeutics On Good Cynviloq Potential

Share:

In a report published Thursday, MLV & Co. analyst Arlinda Lee initiated coverage on Sorrento Therapeutics (NASDAQ: SRNE) with a Buy rating and $9.00 price target.

In the report, MLV & Co. noted, “We are initiating coverage of SRNE with a Buy rating and $9 price target. We believe that lead product candidate Cynviloq, a next generation paclitaxel, has a 75% chance of showing bioequivalence to CELG's Abraxane (CELG – $-159.94 - not covered), gaining FDA approval, and capturing 25% of the addressable paclitaxel market. Second product candidate resiniferatoxin (RTX), a non-opioid severe pain drug, also contributes to our probability-adjusted valuation.”

Sorrento Therapeutics closed on Wednesday at $5.62.

Latest Ratings for SRNE

DateFirmActionFromTo
Aug 2021HC Wainwright & Co.MaintainsBuy
Jan 2021Alliance Global PartnersInitiates Coverage OnBuy
Jul 2020HC Wainwright & Co.MaintainsBuy

View More Analyst Ratings for SRNE

View the Latest Analyst Ratings

 

Related Articles (SRNE)

View Comments and Join the Discussion!

Posted-In: Arlinda Lee MLV & Co.Analyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com